Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 19-1977

More information available at ClinicalTrials.gov: NCT03975647

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers